123 related articles for article (PubMed ID: 31128210)
21. In Vitro Inhibition of Human UDP-Glucuronosyl-Transferase (UGT) Isoforms by Astaxanthin, β-Cryptoxanthin, Canthaxanthin, Lutein, and Zeaxanthin: Prediction of in Vivo Dietary Supplement-Drug Interactions.
Zheng YF; Min JS; Kim D; Park JB; Choi SW; Lee ES; Na K; Bae SK
Molecules; 2016 Aug; 21(8):. PubMed ID: 27529203
[TBL] [Abstract][Full Text] [Related]
22. Interactions between human UDP-glucuronosyltransferase (UGT) 2B7 and UGT1A enzymes.
Fujiwara R; Nakajima M; Oda S; Yamanaka H; Ikushiro S; Sakaki T; Yokoi T
J Pharm Sci; 2010 Jan; 99(1):442-54. PubMed ID: 19475557
[TBL] [Abstract][Full Text] [Related]
23. Everolimus-inhibited multiple isoforms of UDP-glucuronosyltransferases (UGTs).
Du Z; Wang G; Cao YF; Hu CM; Yang K; Liu YZ; Zhang CZ; Zhang WH; Zhu ZT; Sun HZ; Sun XY; Hong M; Fang ZZ
Xenobiotica; 2018 May; 48(5):452-458. PubMed ID: 28548030
[TBL] [Abstract][Full Text] [Related]
24. Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10.
Watanabe Y; Nakajima M; Yokoi T
Drug Metab Dispos; 2002 Dec; 30(12):1462-9. PubMed ID: 12433820
[TBL] [Abstract][Full Text] [Related]
25. Human UDP-glucuronosyltransferase isoforms involved in haloperidol glucuronidation and quantitative estimation of their contribution.
Kato Y; Nakajima M; Oda S; Fukami T; Yokoi T
Drug Metab Dispos; 2012 Feb; 40(2):240-8. PubMed ID: 22028316
[TBL] [Abstract][Full Text] [Related]
26. Characterization of rat and human UDP-glucuronosyltransferases responsible for the in vitro glucuronidation of diclofenac.
King C; Tang W; Ngui J; Tephly T; Braun M
Toxicol Sci; 2001 May; 61(1):49-53. PubMed ID: 11294973
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of UDP-glucuronosyltransferases in rat liver microsomes by natural mutagens and carcinogens.
Grancharov K; Engelberg H; Naydenova Z; Müller G; Rettenmeier AW; Golovinsky E
Arch Toxicol; 2001 Dec; 75(10):609-12. PubMed ID: 11808922
[TBL] [Abstract][Full Text] [Related]
28. Screening of non-steroidal anti-inflammatory drugs for inhibitory effects on the activities of six UDP-glucuronosyltransferases (UGT1A1, 1A3, 1A4, 1A6, 1A9 and 2B7) using LC-MS/MS.
Joo J; Kim YW; Wu Z; Shin JH; Lee B; Shon JC; Lee EY; Phuc NM; Liu KH
Biopharm Drug Dispos; 2015 May; 36(4):258-64. PubMed ID: 25522350
[TBL] [Abstract][Full Text] [Related]
29. UDP-glucuronosyltransferase (UGT) 1A1 mainly contributes to the glucuronidation of trovafloxacin.
Fujiwara R; Sumida K; Kutsuno Y; Sakamoto M; Itoh T
Drug Metab Pharmacokinet; 2015 Feb; 30(1):82-8. PubMed ID: 25760534
[TBL] [Abstract][Full Text] [Related]
30. Human and rat liver UDP-glucuronosyltransferases are targets of ketoprofen acylglucuronide.
Terrier N; Benoit E; Senay C; Lapicque F; Radominska-Pandya A; Magdalou J; Fournel-Gigleux S
Mol Pharmacol; 1999 Jul; 56(1):226-34. PubMed ID: 10385704
[TBL] [Abstract][Full Text] [Related]
31. Regioselective glucuronidation of denopamine: marked species differences and identification of human udp-glucuronosyltransferase isoform.
Kaji H; Kume T
Drug Metab Dispos; 2005 Mar; 33(3):403-12. PubMed ID: 15608137
[TBL] [Abstract][Full Text] [Related]
32. The effect of valproic acid on drug and steroid glucuronidation by expressed human UDP-glucuronosyltransferases.
Ethell BT; Anderson GD; Burchell B
Biochem Pharmacol; 2003 May; 65(9):1441-9. PubMed ID: 12732356
[TBL] [Abstract][Full Text] [Related]
33. Hepatic UDP-glucuronosyltransferases responsible for glucuronidation of thyroxine in humans.
Kato Y; Ikushiro S; Emi Y; Tamaki S; Suzuki H; Sakaki T; Yamada S; Degawa M
Drug Metab Dispos; 2008 Jan; 36(1):51-5. PubMed ID: 17908920
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of the in vitro/in vivo drug interaction potential of BST204, a purified dry extract of ginseng, and its four bioactive ginsenosides through cytochrome P450 inhibition/induction and UDP-glucuronosyltransferase inhibition.
Zheng YF; Bae SH; Choi EJ; Park JB; Kim SO; Jang MJ; Park GH; Shin WG; Oh E; Bae SK
Food Chem Toxicol; 2014 Jun; 68():117-27. PubMed ID: 24632066
[TBL] [Abstract][Full Text] [Related]
35. Inhibitory Effect of Sauchinone on UDP-Glucuronosyltransferase (UGT) 2B7 Activity.
You BH; Gong EC; Choi YH
Molecules; 2018 Feb; 23(2):. PubMed ID: 29425147
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of Human UDP-Glucuronosyltransferase Enzymes by Canagliflozin and Dapagliflozin: Implications for Drug-Drug Interactions.
Pattanawongsa A; Chau N; Rowland A; Miners JO
Drug Metab Dispos; 2015 Oct; 43(10):1468-76. PubMed ID: 26180128
[TBL] [Abstract][Full Text] [Related]
37. Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism.
Picard N; Ratanasavanh D; Prémaud A; Le Meur Y; Marquet P
Drug Metab Dispos; 2005 Jan; 33(1):139-46. PubMed ID: 15470161
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of cytochrome P450 and uridine 5'-diphospho-glucuronosyltransferases by MAM-2201 in human liver microsomes.
Kong TY; Kim JH; Kwon SS; Cheong JC; Kim HS; In MK; Lee HS
Arch Pharm Res; 2017 Jun; 40(6):727-735. PubMed ID: 28484907
[TBL] [Abstract][Full Text] [Related]
39. Inhibitory potential of nonsteroidal anti-inflammatory drugs on UDP-glucuronosyltransferase 2B7 in human liver microsomes.
Mano Y; Usui T; Kamimura H
Eur J Clin Pharmacol; 2007 Feb; 63(2):211-6. PubMed ID: 17200831
[TBL] [Abstract][Full Text] [Related]
40. Involvement of multiple UDP-glucuronosyltransferase 1A isoforms in glucuronidation of 5-(4'-hydroxyphenyl)-5-phenylhydantoin in human liver microsomes.
Nakajima M; Sakata N; Ohashi N; Kume T; Yokoi T
Drug Metab Dispos; 2002 Nov; 30(11):1250-6. PubMed ID: 12386132
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
